Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA EBITDA Margin

EBITDA as a percentage of revenue.

Prothena Corporation plcNASDAQ: PRTA

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 65.9%

EBITDA Margin was 65.9% in Q1 FY2026, up 2228.2 pp from a year earlier. On a trailing-twelve-month basis it was -129.0%, down 45.6 pp year over year. Over 3 fiscal years it narrowed by 1804.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -0.3% for the fiscal year ending Dec 2026, up from -2035.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
65.9%+98337.3 pp QoQ
Last fiscal yearDec 2025
-2035.6%-1940.9 pp YoY
LTMMar 2026
-129.0%-45.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2228.2 pp-3553.4 pp-5781.6 pp
1 year-1940.9 pp+2035.3 pp+3976.1 pp
3 years-1804.0 pp+1950.6 pp+3754.5 pp
5 years+2075.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2035.6%
Year-over-year change
-1940.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PRTA compares with its peers on the latest reported figures

  • PRTA's LTM Mar 2026 EBITDA Margin of -129.0% is the 2nd highest of the 4 companies compared; the peer median is -1740.8%.
  • Its year-over-year change of -45.6 pp is the 2nd highest of 3, against a peer median of -789.7 pp.
  • Over three fiscal years its change of -1804.0 pp compares with a peer median of -86.1 pp.
PRTA Competitors Peer median
EBITDA Margin for PRTA and competitors
Company Period LTM level YoY 3-year change
BIIBBiogen Inc.LTM Jun 202619.7% -14.2 pp-4.7 pp
PRTAProthena Corporation plcLTM Mar 2026-129.0% -45.6 pp-1804.0 pp
ACIUAC Immune S.A.LTM Mar 2026-1740.8% -1565.2 pp-167.5 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-13823.7% ——
ANNXAnnexon, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
PMNProMIS Neurosciences, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding PRTA) -1740.8%-789.7 pp-86.1 pp

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.